Economic burden of multiple sclerosis
Abstract
Multiple sclerosis (MS) is a chronic, inflammatory disease of the central nervous system which has a major impact on quality of life of an individual. It affects young people and is the commonest cause of disability in the age group. Economic burden of MS is high. Modern immunomodulatory drugs are a major generator of costs in early stages of the disease. In patients with more severe disability costs of patients care and sympotmatic treatment and indirect costs because of early retirement prevail. Economic burden of MS strongly correlates with disability, therefore interventions aimed at delaying the progression of the disease and development of new disease-modifying drugs may reduce costs associated with the disease.
Downloads
References
Compston A, Coles A. Multiple sclerosis. Lancet 2008;372:1502-1517.
Olesen J, Gustavsson A, Svensson M, Wittchen HU, Jonsson B. The economic cost of brain disorders in Europe. Eur J Neurol 2012;19:155-62.
Bon J, Koritnik B, Bresjanac M, Repovš G, Pregelj P, Dobnik B, Pirtošek Z. Stroški možganskih bolezni v Sloveniji v letu 2010. Zdrav Vestn 2013;82:164-75.
Auty A, Belanger C, Bouchard JP. Burden of illness of multiple sclerosis: part II. Quality of life. Can J Neurol Sci 1998;25:31-8.
Miltenburger C, Kobelt G. Quality of life and cost of multiple sclerosis. Clin Neurol Neurosurg 2002;104:272-5.
Stolp-Smith KA, Atkinson EJ, Campion ME, O´Brien PC, Rodriguez M. Health care utilization in multiple sclerosis: a population-based study in Olmsted County, MN. Neurology 1998;50:1594-600.
Kobelt G. Costs and quality of life for patients with multiple sclerosis in Belgium. Eur J Health Econ 2006;7 Suppl 2:S24-33.
Kobelt G, Berg J, Lindgren P, Battaglia M, Lucioni C, Uccelli A. Costs and quality of life of multiple sclerosis in Italy. Eur J Health Econ 2006;7 Suppl 2:S45-54.
Kobelt G, Berg J, Lindgren P, Plesnilla C, Baumhackl U, Berger T, et al. Costs and quality of life of multiple sclerosis in Austria. Eur J Health Econ 2006;7 Suppl 2:S14-23.
Kobelt G, Berg J, Lindgren P, Anten B, Ekman M, Jongen PJ, et al. Costs and quality of life of multiple sclerosis in the Netherlands Eur J Health Econ 2006;7 Suppl 2:S55-64.
Palmer AJ, Colman S, O´Leary B, Taylor BV, Simmons RD. The economic impact of multiple sclerosis in Australia in 2010; Mult Scler 2013;19:1640-6.
Naci H, Fleurence R, Birt J, Duhig A. Economic burden of multiple sclerosis. A systematic review of the literature. Pharmacoeconomics 2010;28:363-379.
Goodin DS, Ebers GC, Cutter G, Cook SD, O´Donnell T, Reder AT, et al. Cause of death in MS: long-term follow-up of a randomised cohort, 21 years after the start of the pivotal interferon beta-1b study. BMJ Open 2012; Nov 30;2(6).
Tedeholm H, Lycke J, Skoog B, Lisovskaja V, Hillert J, Dahle C, et al. Time to secondary progression in patients with multiple sclerosis treated with first generation immunomodulating drugs and historical controls adjusted for clinical covariates. Mult Scler 2013;19:765-74.
Bergamaschi R, Quaglini S, Tavazzi E, Amato MP, Paolicelli D, Zipoli V, et al. Immunomodulatory therapies delay disease progression in multiple sclerosis. Mult Scler 2012; Epub ahead of print.
Shirani A, Zhao Y, Karim M, Evans C, Kingwell E, van der Kop ML, et al. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis. JAMA 2012;308:247-56.
Kobelt G, Berg J, Lindgren P, Izquierdo G, Sanchez-Solino O, Perez-Miranda J, Casado MA. Cost and quality of life of multiple sclerosis in Spain. Eur J Health Econ 2006;7:Suppl2:S65-74.
O´Brien JW, Ward AJ, Patrick AR, Caro J. Cost of managing an episode of relapse in multiple sclerosis in the United States BMC Health Serv Res 2003;17.
Amato MP, Battaglia MA, Caputo D, Fattore G, Gerzeli S, Pitaro M, et al. The costs of multiple sclerosis: a cross-sectional, multicenter cost-of-illness study in Italy. J Neurol 2002;249:152-63.
Carton H, Loos R, Pacolet J, Versieck K, Vlietnick R. Utilisation and cost of professional care and assistance according to disability of patients with multiple sclerosis in Flanders (Belgium). J Neurol Neurosurg Psychiatry 1998;64:444-50.
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
